SEC Comment Letter for Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Feb 1, 2018
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Feb. 1, 2018 · CIK: 0001512762 · Accession: 0000000000-18-003758
AI Filing Summary & Sentiment
Reasoning
Letter
February 1, 2018 Dennis M. Lanfear President and Chief Executive Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 Coherus BioSciences, Inc. Registration Statement on Form S-3 Filed January 25, 2018 File No. 333-222698Re: Dear Mr. Lanfear: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Benjamin A. Potter, Esq.
Show Raw Text
February 1, 2018
Dennis M. Lanfear
President and Chief Executive Officer
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
Coherus BioSciences, Inc.
Registration Statement on Form S-3
Filed January 25, 2018
File No. 333-222698Re:
Dear Mr. Lanfear:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Benjamin A. Potter, Esq.